|
Dr. Samuel E. Lynch Presides Over the NASDAQ Closing Bell to Celebrate the Initial Public Offering of BioMimetic Therapeutics, Inc. [BMTI] 
Where NASDAQ MarketSite – 4 Times Square (43rd & Broadway) When
About BioMimetic Therapeutics [BMTI] BioMimetic Therapeutics, Inc. develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in November 2005 for its first product GEM 21S® as a grafting material for bone and periodontal regeneration. A pivotal human clinical trial demonstrated the safety and efficacy of its platform technology in this indication, resulting in significantly faster healing and improved bone healing on clinical X-rays. The Company's product and product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration. The Company believes its regenerative therapies will improve the treatment options and quality of life for millions of patients with injuries or deterioration of bones, cartilage, tendons or ligaments. Contacts Kearstin Patterson BioMimetic Therapeutics Corporate Communications 615.236.4419 -- e-mail for more information Stephanie Lowenthal NASDAQ MarketSite 646.441.5220 Photos To obtain hi-resolution photos pertaining to BioMimetic Therapeutics, please go to our Media Resources Area or to NASDAQ's Market Site Events area to request access and download images. |
